Needham & Company LLC reissued their buy rating on shares of CONMED (NYSE:CNMD – Free Report) in a report issued on Friday, Benzinga reports. They currently have a $97.00 price objective on the stock.
Several other equities research analysts have also recently commented on CNMD. Wells Fargo & Company lowered their target price on CONMED from $77.00 to $71.00 and set an equal weight rating for the company in a research note on Thursday, August 1st. Piper Sandler lowered their price objective on CONMED from $95.00 to $80.00 and set an overweight rating for the company in a research report on Thursday, August 1st. Stifel Nicolaus cut their target price on shares of CONMED from $88.00 to $76.00 and set a buy rating on the stock in a research report on Thursday, August 1st. Finally, StockNews.com lowered shares of CONMED from a buy rating to a hold rating in a research note on Tuesday, October 1st. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the stock. Based on data from MarketBeat, CONMED presently has a consensus rating of Moderate Buy and an average target price of $79.80.
Get Our Latest Research Report on CNMD
CONMED Stock Down 3.9 %
CONMED (NYSE:CNMD – Get Free Report) last released its quarterly earnings results on Wednesday, July 31st. The company reported $0.98 EPS for the quarter, beating the consensus estimate of $0.92 by $0.06. CONMED had a net margin of 7.73% and a return on equity of 13.89%. The business had revenue of $332.10 million for the quarter, compared to analysts’ expectations of $334.39 million. During the same period in the prior year, the firm earned $0.83 earnings per share. CONMED’s revenue was up 4.5% compared to the same quarter last year. As a group, research analysts forecast that CONMED will post 3.99 EPS for the current fiscal year.
CONMED Announces Dividend
The business also recently disclosed a quarterly dividend, which was paid on Friday, October 4th. Investors of record on Monday, September 16th were issued a $0.20 dividend. The ex-dividend date of this dividend was Monday, September 16th. This represents a $0.80 dividend on an annualized basis and a yield of 1.25%. CONMED’s dividend payout ratio is presently 30.65%.
Institutional Trading of CONMED
A number of hedge funds have recently modified their holdings of the company. Diversified Trust Co grew its holdings in shares of CONMED by 18.0% in the 3rd quarter. Diversified Trust Co now owns 13,275 shares of the company’s stock valued at $955,000 after buying an additional 2,025 shares during the period. SG Americas Securities LLC grew its stake in CONMED by 117.6% in the third quarter. SG Americas Securities LLC now owns 10,924 shares of the company’s stock valued at $786,000 after acquiring an additional 5,903 shares during the period. Sanctuary Advisors LLC bought a new stake in shares of CONMED in the second quarter worth about $913,000. Clearbridge Investments LLC increased its holdings in shares of CONMED by 23.4% in the second quarter. Clearbridge Investments LLC now owns 421,465 shares of the company’s stock worth $29,216,000 after acquiring an additional 80,025 shares in the last quarter. Finally, Creative Planning raised its position in shares of CONMED by 83.6% during the second quarter. Creative Planning now owns 7,136 shares of the company’s stock worth $495,000 after purchasing an additional 3,250 shares during the period.
CONMED Company Profile
CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for surgical procedures worldwide. The company offers orthopedic surgery products, including BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors, which provide clinical solutions to orthopedic surgeons for the augmentation and repair of soft tissue injuries, as well as provides supporting products that enable surgeons to perform minimally invasive sports medicine surgeries.
Featured Stories
- Five stocks we like better than CONMED
- How to Know if a Stock Pays Dividends and When They Are Paid Out
- Ciena Stock Powers the AI Cloud Boom—Don’t Miss Out
- Best Stocks Under $10.00
- Affirm’s Path to Profitability Elevates with Interest Rate Cuts
- Investing in Travel Stocks Benefits
- RPM International Thrives in Rate-Cut Driven Construction Rally
Receive News & Ratings for CONMED Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CONMED and related companies with MarketBeat.com's FREE daily email newsletter.